Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 July 2023 | Story Leonie Bolleurs | Photo André Damons
Dr Jerry Mofokeng
Dr Jerry Mofokeng wa Makhetha recently launched his second book, Nna Ke Monna, during an event at the UFS.

Award-winning actor and now author, Dr Jerry Mofokeng wa Makhetha, launched his second book Nna Ke Monna at an event hosted by the University of the Free State (UFS) Department of Library and Information Services (LIS), the African Languages Press, and the Academy for Multilingualism

The event took place on 19 July on the Bloemfontein Campus.

The book launch was held as part of a creative writing masterclass and drew notable attendees, including dignitaries from Lesotho. Among them was the Honourable Minister of Trade and Industry in Lesotho, Shelile Motaung, and the British High Commissioner in Lesotho, Harry MacDonald.

Earlier last week, Jeannet Molopyane, Director of LIS, and her team handed a copy of the book to the Vice-Chancellor and Principal, Prof Francis Petersen. 

Writing in Sesotho

Out of a collection of more than 200 000 books, only 16 000 are written in Sesotho. Dr Mofokeng wa Makhetha highlighted that the UFS should take a leading role in promoting the publication of African languages.

Addressing the importance of decolonising education, he asked, ‘how do you do that? “We need to go back to our language and our culture. This is what this book seeks to correct and heal,” he answered. 

Unlike his first book, I am a man, where he delved into his intricate relationship with masculinity, fatherhood, and identity, this new book is written in Sesotho, not English.

I do not want anybody reading this latest book to sit with a dictionary to understand it. It was written for the Basotho pallet, to be read by all members of the family.
“As a Sesotho, I have the authority to talk to the Basotho and I don’t want to do that in a manner that anyone must interpret what I am saying.”

He went on to explain that he chose to write this book in Sesotho, because – with the first book – he found that there are thoughts that are difficult to express in English. The English book was a compromise in many ways, and with this book he wanted to reclaim his authentic voice and really have fun.

MacDonald also contributed to the language discussion, saying that the way in which we express ourselves is coloured by our language. He said being able to work in one's own language, such as this book, is a crucial aspect of reflecting one's culture and facilitates faster learning during childhood.

Molopyane, regarded the event as an opportunity to restore the dignity of our languages. Building upon Molopyane's statement, Kego Phuthi, Marketing and Engaged Scholarship Assistant Director in LIS, added that the book launch is reflecting on the significance of literature as a catalyst of change. “The book is an extraordinary work that can change stereotypes and give voice to the voiceless.”
 
Healing masculinity 

In addition to addressing language, the book also emphasised the significance of manhood and the process of healing masculinity. “We are here to raise responsible men with integrity, not big boys,” Dr Mofokeng wa Makhetha said.

According to Nthabiseng Jafta, the publicist of Nna Ke Monna, this book was released one year after Dr Mofokeng wa Makhetha’s first book and coincided with the launch of the African Languages Press.

“During the process of working on the second book, Dr Mofokeng wa Makhetha guided me to reconnect with myself,” said Jafta. She also expressed pride in contributing to the potential impact of Sesotho literature in the nation.

In his address, the Honourable Minister Motaung shared the same sentiment, encouraging Dr Mofokeng wa Makhetha to continue publishing books that uplift the Basotho community.

  • The award-winning South African actor, who appeared in the films Cry, the Beloved Country, Mandela and De Klerk, and Tsotsi, received an honorary doctorate from the UFS in 2019 for his commitment to scholarship and his service to humanity. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept